THERAVIA acquired by NORGINE

Private equity firm Mérieux Equity Partners has entered into a definitive agreement to divest its controlling equity stake in the pharmaceutical laboratory Theravia to the Dutch group Norgine, a portfolio company backed by Goldman Sachs Asset Management. Representing the sixth exit for the Mérieux Equity Participations 3 fund, this transaction facilitates the complete exit of the sponsor, which had held a near-80% ownership position since Theravia's inception through a corporate merger in 2022. The completion of the deal remains subject to the receipt of customary regulatory approvals. For the acquirer Norgine, led by CEO Janneke van der Kamp, this integration is a core component of its expansion strategy, designed to solidify its standing as a partner of choice for the commercialization of specialty pharmaceuticals across Europe. Theravia’s innovative treatments, such as Orphacol and Siklos, perfectly complement Norgine’s existing pipeline—which already features therapies like Pedmarqsi and Mavorixafor. This highly synergistic combination expands the group's core rare disease franchise to a total of six strategic products. For Theravia and its CEO Franck Hamalian, partnering with an established industrial player boasting substantial European commercial firepower provides a critical opportunity to accelerate patient access to life-saving medications for severe unmet medical needs, driven by a shared strategic vision for continuous innovation in the rare disease sector.

In the past, Theravia underwent an LBO led by Merieux Equity Partners in 2022.